MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

Home » J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study

J&J touts NEJM publication of 5-year Type II diabetes bariatric surgery study

By

EthiconJohnson & Johnson (NYSE:JNJ) said today that 5-year results from the Ethicon-funded Stampede trial exploring the benefits of bariatric surgery and intensive medical therapy for diabetes patients were published in the New England Journal of Medicine.

The trial aimed to explore the use of bariatric surgery and medical therapy for obese Type II diabetes patients with a BMI of greater than or equal to 27, according to Johnson & Johnson.

At 5 years, patients who underwent bariatric surgery reported sustained gylcemic control improvements and less diabetes medications, according to the study.

“The landmark Stampede study, along with other studies supported by Ethicon, provide the high level evidence that inform and influence treatment options. The American Diabetes Association’s newly updated Standards of Care in Diabetes is the most recent example of how research matters, and how studies like Stampede are impacting the standard of care,” J&J therapeutic area lead for metabolics Dr. Elliott Fegelman said in a prepared statement.

J&J’s Ethicon said it will continue to explore the effectiveness of bariatric and metabolic surgery with the ARMMS study, which when combined with the Stampede and 3 other trials will provide data on the impact of such surgeries for up to 10 years.

“With the new guidelines from ADA and other major diabetes organizations, type 2 diabetes officially becomes an operable disease and bariatric/metabolic surgery a standard-of-care treatment. This is truly a historic development. It is crucial that primary care physicians, policy makers and the public at large be made aware of the new guidelines so that appropriate surgical candidates can have access to a clinically proven and cost-effective form of diabetes treatment,” Dr. Francesco Rubino of King’s College London said in a press release.

J&J’s Ethicon subsidiary said last month it won FDA 510(k) clearance for its Echelon Flex 45mm endocutter with proprietary gripping surface technology.

The clearance follows an earlier pass by the federal agency for Ethicon’s Echelon Flex 60mm powered plus stapler. With the new clearance, Echelon’s Flex GST system offers both 45mm and 60mm endocutters with exclusive reloads.

In case you missed it

RSS From Medical Design & Outsourcing

  • COVID-19 test makers say their products also detect Omnicron
    Abbott, BD, Hologic, PerkinElmer and Thermo Fisher are reassuring the public that their COVID-19 tests detect the Omnicron variant. Discovered last week in South Africa, the new variant has enough mutations that it has raised concerns worldwide — even though it is still unknown for sure whether the mutations cause greater transmissibility or vaccine evasion.… […]
  • November 2021 Issue: The Big 100 – Medtech’s 100 Largest Players
      Browse the online version of the Big 100 An even larger medtech supply chain shock looms beyond the pandemic European approval ‘a big deal’ as Medtronic moves forward with Hugo surgical robot How medtech fared in the first waves of the pandemic People move the medtech industry forward The term “supply chain” brings to… […]
  • Could winged microchips monitor for airborne disease?
    Northwestern University engineers have created what they claim are the smallest-ever human-made flying structures — winged microchips that could monitor the air for disease and pollution. Engineering professor John Rogers and his team at Northwestern drew on inspiration from nature to create the microchips, which are the size of a grain of sand. The chips… […]
  • Smith+Nephew expands reach of its Cori handheld robotic system
    A year after Smith+Nephew (NYSE:SNN) launched its Cori handheld robotic system in the U.S.,  the ortho surgery system has launched globally. The British medtech giant has expanded Cori’s reach to Europe, Australia and New Zealand, India, and Canada (just announced today). The company yesterday said the system was now available for use in the U.K.’s National Health… […]
  • Elizabeth Holmes reportedly expresses remorse in criminal fraud trial
    Elizabeth Holmes reportedly revealed some regret over her handling of business as the ex-Theranos CEO took the stand again in a criminal fraud trial. Taking the stand yesterday for the third day of testimony in federal court in San Jose, California, Holmes was said to have shown remorse while still shifting some of the blame… […]
  • Supply chain, manufacturing issues slow Medtronic’s Hugo launch, ramp-up expected next fiscal year
    Medtronic (NYSE:MDT) Chair & CEO Geoff Martha confirmed that the launch of the Hugo surgical robot platform is off-schedule. Hugo received CE mark approval last month. The company is gearing up to conduct its FDA investigational device exemption (IDE) clinical trials in the U.S., with more on its stateside efforts still to come, Medtronic’s surgical robotics… […]
  • Minnetronix Medical honored in Minnesota for its MindsEye Expandable Port
    Minnetronix Medical (St. Paul, Minn.) received an award from the Minnesota Technology Association that highlights its MindsEye Expandable Port for minimally invasive deep brain access. The company won the association’s TEKNE award for best medical technology and devices. “Given Minnesota is a global epicenter for the medical device industry, this award is quite meaningful to Minnetronix… […]
  • BD expands biosciences business with reagent innovation center in San Diego
    A life sciences real estate developer announced today that BD (NYSE:BDX) selected its property as a new facility for its biosciences business. Through a joint venture with Tishman Speyer and Bellco Capital, Breakthrough Properties confirmed that BD chose its Torrey View by Breakthrough property for an expanded San Diego reagent innovation center within its biosciences… […]
  • The best places to work for medtech sales reps in 2022
    Teleflex (NYSE:TFX), ConMed (NSDQ:CNMD) and Medtronic (NYSE:MDT) topped the list of best places to work in medtech sales in 2022, according to a MedReps.com survey of medical sales representatives. The 11th annual MedReps survey polled over 2,300 MedReps professionals to determine which medtech sales companies are most sought-after in the industry. Overall, pay and leadership were the most… […]
  • How medtech fared in the first waves of the pandemic
    Medtech industry revenue, research spending and employment declined in the first year of the COVID-19 pandemic, according to a Medical Design & Outsourcing analysis of financial data. Total sales, R&D spending and employment for the world’s largest medical device companies declined in 2020 and early 2021, according to a Medical Design & Outsourcing analysis tallying… […]
  • FreeStyle Libre 3, other Abbott products recognized at CES Innovation Awards
    Abbott (NYSE:ABT) was honored for a handful of its offerings at the Consumer Electronics Show (CES) 2022 Innovation Awards. The company’s FreeStyle Libre 3 continuous glucose monitoring (CGM) system ranked among the top 15 products in the CES Best of Innovation category. The next-generation CGM system features the world’s smallest, thinnest glucose sensor that can… […]